Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many cancers, enabling long-term remission and potentially curative responses. But there’s a downside: these drugs also can result in inflammatory syndromes known as immune-related adverse events (irAEs). Of rheumatic irAEs, the most common is ICI-induced inflammatory arthritis (ICI-IA). Our program has been investigating and treating ICI-IA and other rheumatic irAEs since 2015.
ICIs are here to stay, and so are irAEs.